Home » Topics » Regulatory » EMA

EMA
RSS

Novartis Europharm withdraws Rasival MAA for essential hypertension

Sep. 21, 2010

GSK investigates reports of narcolepsy following Pandemrix vaccination

Sep. 6, 2010

MSD's Sycrest approved in Europe for biopolar disorder

Sep. 3, 2010

FDA approves Bionovo's CMC plan for Menerba

Aug. 31, 2010

EMA investigates potential relationship between Pandemrix and narcolepsy

Aug. 30, 2010

European Commission updates license for Cervarix HPV vaccine

Aug. 30, 2010

Shire's VPRIV approved in Europe for type 1 Gaucher's disease

Aug. 27, 2010

Bristol-Myers Squibb offers pipeline update for Q2 2010

Aug. 24, 2010

Amsterdam Molecular Therapeutics provides update on Glybera MAA

Aug. 23, 2010

EMA accepts Optimer Pharma's fidaxomicin MAA for review

Aug. 20, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.